Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

ain other Asian markets) for rheumatoid arthritis, early rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, pediatric Crohn's disease and ulcerative colitis.

Global sales of NASONEX, an inhaled nasal corticosteroid for allergies, increased 3 percent to $321 million in the 2009 second quarter (10 percent operational growth offset by 7 percent unfavorable foreign exchange impact) as compared to $311 million in the second quarter of 2008. Operational sales were strong in both the U.S. and internationally as compared to the 2008 period.

Sales of TEMODAR, a treatment for certain types of brain tumors, increased 2 percent (11 percent operational growth offset by 9 percent unfavorable foreign exchange impact) to $256 million, with higher sales in the U.S. and Japan.

Sales of PEGINTRON for hepatitis C decreased 6 percent to $215 million in the 2009 second quarter, primarily due to the unfavorable foreign exchange impact of 6 percent.

In women's health care, sales of FOLLISTIM/PUREGON, a fertility treatment, for the second quarter of 2009 decreased 11 percent (1 percent operational decrease and 10 percent unfavorable foreign exchange impact) to $145 million as compared to the second quarter of 2008. Sales of NUVARING, a contraceptive product, in the second quarter of 2009 increased 11 percent (19 percent operational growth offset by 8 percent unfavorable foreign exchange impact) to $129 million as compared to $116 million in the second quarter of 2008.

Global sales of CLARINEX, a nonsedating antihistamine, were $226 million, a decrease of 6 percent (4 percent operational growth offset by 10 percent unfavorable foreign exchange impact) as compared to the second quarter of 2008.

Sales of CLARITIN in the prescription business were $96 million, a 13 percent decrease (6 percent operational decreas
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 MabVax Therapeutics Holdings, Inc. ... that the Company,s lead antibody, HuMab 5B1, will be ... presentations during the upcoming World Molecular Imaging Congress (WMIC) ... 2-5, 2015. Researchers from the Department of Radiology at ... on the use of MabVax,s lead antibody as a ...
(Date:8/31/2015)... , Aug. 31, 2015  For people with ... brighten their day. The biotechnology company, located in the ... one of the best potential therapies yet for people ... entitled, " Correction of Down syndrome and Edwards syndrome ... journal DNA Research . Elixirgen plans to develop ...
(Date:8/31/2015)... FRANCISCO, Calif. , Aug. 31, 2015 ... discovery and development of novel cancer immunotherapies, announced today ... Ph.D., as Chief Executive Officer and William Ho ... and Ho join an experienced management team led by ... Jordan Fridman , Ph.D., Chief Scientific Officer; Jay ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for ... first commercially available new FDA approved system in the last 14 years, and the ... high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... EXTON, Pa. , Feb. 2 ... company focused on the development of regenerative cell therapy ... David Pernock , Chairman of the Board of ... immediately. Pernock most recently served as Senior Vice President ...
... , , SANTA ROSA, ... Health Month, EcoNugenics introduces the newest ...  The Santa Rosa, CA -based nutraceutical company, founded in 1995 by ... MS, LAc, has once again demonstrated excellence in being at the ...
... , SAN DIEGO , Feb. 1 ... it will report results for its fourth quarter and year ended ... 10, 2010 . , Alan D. Gold , Chairman and ... Officer, will host an investor conference call at 10:00 a.m. Pacific ...
Cached Biology Technology:Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 2Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 3Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 2Just in Time for Heart Health Month... TRIPLE Cardiovascular Health Support From EcoNugenics 3BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results 2
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/11/2015)... Sweden , August 11, 2015 Today, ... FPC1155. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... patients with castration-resistant prostate cancer, the addition of ... compared with either treatment alone or when the ... published in the July 15 Clinical Cancer ... for Cancer Research. Philip M. Arlen, M.D., ...
... fossil and the reinterpretation of previously known fossils, all from ... "missing link" in the evolution of flatfishes and explain one ... include halibut, flounder and sole, have a bizarre structural adaptation: ... is even more remarkable is that every flatfish is born ...
... issue of the journal Nature, the research reveals ... necessary for viral entry into human cells, bound to an ... provides a major step forward in understanding how the deadly ... potential Ebola virus vaccines, or treatments for those infected. ...
Cached Biology News:Prostate cancer vaccines more effective with hormone therapy 2New fossil tells twisted tale of how flatfishes ended up with two eyes on one side of head 2New fossil tells twisted tale of how flatfishes ended up with two eyes on one side of head 3New fossil tells twisted tale of how flatfishes ended up with two eyes on one side of head 4Scripps research scientists reveal key structure from ebola virus 2
... 1. 1000 V, 400 mA, 100 ... constant power modes.Single-unit increments in settings ... and recalls three protocols.Outstanding choice for ... Multiphor II or GenePhor systems. Category: ...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Mouse Nodal Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: